Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma

Lancaster Medical School

Text available via DOI:

https://doi.org/10.1016/j.cellsig.2020.109638
Final published version

Keywords

Decorin, Glioblastoma, Transforming growth factor beta

View graph of relations

Research output: Contribution to Journal/Magazine › Review article › peer-review

Published

Standard

Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma. / Birch, Joanna L.; Coull, Barry J.; Spender, Lindsay C. et al.
In: Cellular Signalling, Vol. 72, 109638, 08.2020, p. 109638.

Research output: Contribution to Journal/Magazine › Review article › peer-review

Harvard

Birch, JL, Coull, BJ, Spender, LC, Watt, C, Willison, A, Syed, N, Chalmers, AJ, Hossain-Ibrahim, MK & Inman, GJ 2020, 'Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma', Cellular Signalling, vol. 72, 109638, pp. 109638. https://doi.org/10.1016/j.cellsig.2020.109638

APA

Birch, J. L., Coull, B. J., Spender, L. C., Watt, C., Willison, A., Syed, N., Chalmers, A. J., Hossain-Ibrahim, M. K., & Inman, G. J. (2020). Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma. Cellular Signalling, 72, 109638. Article 109638. https://doi.org/10.1016/j.cellsig.2020.109638

Vancouver

Birch JL, Coull BJ, Spender LC, Watt C, Willison A, Syed N et al. Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma. Cellular Signalling. 2020 Aug;72:109638. 109638. doi: 10.1016/j.cellsig.2020.109638

Author

Birch, Joanna L. ; Coull, Barry J. ; Spender, Lindsay C. et al. / Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma. In: Cellular Signalling. 2020 ; Vol. 72. pp. 109638.

Bibtex

@article{776e9ab10e934e5f993fede2737b7ff1,

title = "Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma",

abstract = "Glioblastoma (GBM) is an aggressive and devastating primary brain cancer which responds very poorly to treatment. The average survival time of patients is only 14–15 months from diagnosis so there is a clear and unmet need for the development of novel targeted therapies to improve patient outcomes. The multifunctional cytokine TGFβ plays fundamental roles in development, adult tissue homeostasis, tissue wound repair and immune responses. Dysfunction of TGFβ signalling has been implicated in both the development and progression of many tumour types including GBM, thereby potentially providing an actionable target for its treatment. This review will examine TGFβ signalling mechanisms and their role in the development and progression of GBM. The targeting of TGFβ signalling using a variety of approaches including the TGFβ binding protein Decorin will be highlighted as attractive therapeutic strategies.",

keywords = "Decorin, Glioblastoma, Transforming growth factor beta",

author = "Birch, {Joanna L.} and Coull, {Barry J.} and Spender, {Lindsay C.} and Courtney Watt and Alice Willison and Nelofer Syed and Chalmers, {Anthony J.} and Hossain-Ibrahim, {M. Kismet} and Inman, {Gareth J.}",

note = "Funding Information: The authors acknowledge grants from Cancer Research UK (A29802) and Tenovus Tayside , UK. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = aug,

doi = "10.1016/j.cellsig.2020.109638",

language = "English",

volume = "72",

pages = "109638",

journal = "Cellular Signalling",

issn = "0898-6568",

publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma

AU - Birch, Joanna L.

AU - Coull, Barry J.

AU - Spender, Lindsay C.

AU - Watt, Courtney

AU - Willison, Alice

AU - Syed, Nelofer

AU - Chalmers, Anthony J.

AU - Hossain-Ibrahim, M. Kismet

AU - Inman, Gareth J.

PY - 2020/8

Y1 - 2020/8

N2 - Glioblastoma (GBM) is an aggressive and devastating primary brain cancer which responds very poorly to treatment. The average survival time of patients is only 14–15 months from diagnosis so there is a clear and unmet need for the development of novel targeted therapies to improve patient outcomes. The multifunctional cytokine TGFβ plays fundamental roles in development, adult tissue homeostasis, tissue wound repair and immune responses. Dysfunction of TGFβ signalling has been implicated in both the development and progression of many tumour types including GBM, thereby potentially providing an actionable target for its treatment. This review will examine TGFβ signalling mechanisms and their role in the development and progression of GBM. The targeting of TGFβ signalling using a variety of approaches including the TGFβ binding protein Decorin will be highlighted as attractive therapeutic strategies.

AB - Glioblastoma (GBM) is an aggressive and devastating primary brain cancer which responds very poorly to treatment. The average survival time of patients is only 14–15 months from diagnosis so there is a clear and unmet need for the development of novel targeted therapies to improve patient outcomes. The multifunctional cytokine TGFβ plays fundamental roles in development, adult tissue homeostasis, tissue wound repair and immune responses. Dysfunction of TGFβ signalling has been implicated in both the development and progression of many tumour types including GBM, thereby potentially providing an actionable target for its treatment. This review will examine TGFβ signalling mechanisms and their role in the development and progression of GBM. The targeting of TGFβ signalling using a variety of approaches including the TGFβ binding protein Decorin will be highlighted as attractive therapeutic strategies.

KW - Decorin

KW - Glioblastoma

KW - Transforming growth factor beta

UR - http://www.scopus.com/inward/record.url?scp=85083500180&partnerID=8YFLogxK

U2 - 10.1016/j.cellsig.2020.109638

DO - 10.1016/j.cellsig.2020.109638

M3 - Review article

C2 - 32320860

AN - SCOPUS:85083500180

VL - 72

SP - 109638

JO - Cellular Signalling

JF - Cellular Signalling

SN - 0898-6568

M1 - 109638

ER -

Research

Text available via DOI:

Keywords